Increased C-reactive protein level after coronary stent implantation in patients with stable coronary artery disease

Miriam Almagor1, Andre Keren, Shmuel Banai

  • 1Division of Clinical Laboratories, Bikur Cholim Hospital, Jerusalem, Israel.

American Heart Journal
|February 22, 2003
PubMed

Insights

Elective coronary stent implantation in patients with stable coronary artery disease (CAD) significantly elevates C-reactive protein (CRP) levels, indicating a systemic inflammatory response. This finding highlights the impact of plaque disruption on inflammation markers in low-risk patients.

Area of Science:

  • Cardiology
  • Inflammation markers
  • Interventional cardiology

Background:

  • Elevated C-reactive protein (CRP) correlates with cardiac event risk.
  • CRP levels predict mortality in acute coronary syndromes.
  • Investigating CRP response to plaque disruption in stable CAD is crucial.

Purpose of the Study:

  • To determine if mechanical plaque rupture during elective stent implantation in stable coronary artery disease (CAD) patients increases serum CRP levels.
  • To compare CRP response in low-risk stable CAD patients versus those with acute coronary syndromes and diagnostic angiography.

Main Methods:

  • Serum CRP levels measured in 40 patients undergoing coronary procedures.
  • Group 1: 12 low-risk stable CAD patients undergoing stent implantation.
  • Groups 2 & 3: Control groups with acute coronary syndrome undergoing stenting and stable/unstable CAD undergoing angiography without stenting.

Main Results:

  • Stable CAD patients (Group 1) showed a 4.9-fold CRP increase post-stenting (P <.002).
  • Acute coronary syndrome patients (Group 2) had a smaller, less uniform CRP increase (2.1-fold, P <.004).
  • Diagnostic angiography patients (Group 3) showed no significant CRP elevation post-procedure.

Conclusions:

  • Mechanical disruption of atherosclerotic plaque during elective stenting in stable CAD patients triggers a significant inflammatory response.
  • This response is evidenced by a marked elevation in serum CRP concentration.
  • The inflammatory response is more pronounced in stable CAD patients undergoing stenting compared to other groups.
Abstract

Related Concept Videos

Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...